GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                                     
                            
                            
                            
                                 Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: PF-06939999 is an orally bioavailable, SAM-competitive PRMT5 inhibitor that was developed for ant-tumour potential [1].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| No information available. | 
Summary of Clinical Use ![]()  | 
                                                        
| PF-06939999 has been advanced to clinical evaluation in splicing dysregulated non-small cell lung cancers. | 
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References | 
| NCT03854227 | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | Phase 1 Interventional | Pfizer | ||